Posted on November 04, 2013
NCI scientists report that two doses of a human papillomavirus (HPV) vaccine, trademarked as Cervarix, resulted in similar serum antibody levels against two of the most carcinogenic types of HPV (16 and 18), compared to a standard three dose regimen. The results appeared in the November 2013 issue of Cancer Prevention Research.
NCI Press Release: Fewer doses of HPV vaccine result in immune response similar to three-dose regimen
The National Cancer Institute (NCI) press note for the study